COMP <GO>
BEAM vs TARS // RSI-14 & 200D SMA MOMENTUM
Beam Therapeutics Inc. (NASDAQ) VS. Tarsus Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: BEAM 1
— TARS 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: BEAM
LAST: $27.23 (-5.58%) • MKT CAP: $2.98B
rsi-technicals
63.0
LAST: $74.85 (+0.88%) • MKT CAP: $3.66B
rsi-technicals
53.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BEAM VS. TARS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BEAM | TARS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.10% | -24.10% | -8.00 | TARS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.09% | -0.61% | -11.48 | TARS | /fcf-yield <GO> |
| Operating Margin | -60.00% | -15.70% | -44.30 | TARS | /operating-margins <GO> |
| Net Profit Margin | -57.20% | -14.60% | -42.60 | TARS | /net-margins <GO> |
| Revenue Growth (YoY) | 120.00% | 146.70% | -26.70 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.00 | 10.19 | -4.19 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | TARS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 63.0 | 53.4 | +9.60 | BEAM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.98B | $3.66B | -$679.5M | TARS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BEAM REV | TARS REV | BEAM GROSS % | TARS GROSS % | BEAM FCF | TARS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $139.7M | $451.4M | — | — | -$360.0M | -$22.3M |
| FY 2024 | $63.5M | $183.0M | — | — | -$356.2M | -$84.6M |
| FY 2023 | $377.7M | $17.4M | — | — | -$149.2M | -$117.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BEAM // BETA —
TARS // BETA —